Skip to main content
SpringerLink
Log in

CCN1: a novel target for pancreatic cancer

  • Bits and Bytes
  • Published:
Journal of Cell Communication and Signaling Aims and scope

Abstract

Members of CCN family of matricellular proteins are being increasingly recognized by the translational research community as representing excellent targets for drug intervention. Although much effort has been expended in outlining the mechanisms involved in pancreatic carcinogenesis, the precise molecular pathways involved remain incompletely understood, and appropriate targets for drug intervention remain elusive. A recent exciting report by Haque and colleagues (Mol Cancer. 2011 Jan 13;10:8) provides strong evidence that CCN1 (cyr61) is a potential therapeutic target in pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M (2006) Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 5:1108–16

    Article  PubMed  CAS  Google Scholar 

  • Babic AM, Kireeva ML, Kolesnikova TV, Lau LF (1998) CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 95:6355–6360

    Article  PubMed  CAS  Google Scholar 

  • Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, Feazell J, Yang GP, Koong A, Giaccia AJ (2009) The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 69:775–84

    Article  PubMed  CAS  Google Scholar 

  • Chen N, Leu SJ, Todorovic V, Lam SC, Lau LF (2004) Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem 279:44166–76

    Article  PubMed  CAS  Google Scholar 

  • Franzen CA, Chen CC, Todorović V, Juric V, Monzon RI, Lau LF (2009) Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol Cancer Res 7:1045–55

    Article  PubMed  CAS  Google Scholar 

  • Gregory PA, Bracken CP, Bert AG, Goodall GJ (2008) MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7:3112–8

    Article  PubMed  CAS  Google Scholar 

  • Haque I, Mehta S, Majumder M, Dhar K, De A, McGregor D, Van Veldhuizen PJ, Banerjee SK, Banerjee S (2011) Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer 10:8

    Article  PubMed  CAS  Google Scholar 

  • Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, Fleming JB (2005) Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 200:371–7

    Article  PubMed  Google Scholar 

  • Huang W, Gonzalez ME, Toy KA, Banerjee M, Kleer CG (2010) Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells. Cancer Res 70:3340–50

    Article  PubMed  CAS  Google Scholar 

  • Leask A (2009) Death of a tumor: targeting CCN in pancreatic cancer. J Cell Commun Signal 3:159–160

    Article  PubMed  Google Scholar 

  • Leask A (2010) CCN6 (WISP3): a new anti-cancer therapy? J Cell Commun Signal 4:199–200

    Article  PubMed  Google Scholar 

  • Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049–57

    Article  PubMed  CAS  Google Scholar 

  • Pickles M, Leask A (2007) Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK. J Cell Commun Signal 1:85–90

    Article  PubMed  Google Scholar 

  • Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R (2002) (2002) Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21:8178–8185

    Article  PubMed  CAS  Google Scholar 

  • Xie D, Yin D, Tong X, O’Kelly J, Mori A, Miller C, Black K, Gui D, Said JW, Koeffler HP (2004) Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 64:1987–1996

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CIHR Group in Skeletal Development and Remodeling, Division of Oral Biology and Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Dental Sciences Building, University of Western Ontario, London, ON, Canada, N6A 5C1

    Andrew Leask

Authors
  1. Andrew Leask
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Leask.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leask, A. CCN1: a novel target for pancreatic cancer. J. Cell Commun. Signal. 5, 123–124 (2011). https://doi.org/10.1007/s12079-011-0127-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12079-011-0127-1

Keywords

Search

Navigation